バカラツリー

<ウェブサイト名>

<現在の時刻>

出典: 標準

Researchers Details of a Researcher Home Japanese このページはJavascriptを使用しています。すべての機能を使用するためにはJavascript を有効にする必要があります。   Personnel Information   Profile   Degree   Research Areas   From School   Studying abroad experiences   Employment Record in Research   External Career   Professional Memberships   Research Activity   Research Career   Papers   Books and Other Publications   Misc   Presentations   Scientific Research Funds Acquisition Results   Contribution to Society   Social Activities Updated on 2023/09/29 WATANABE Chie Affiliation Faculty of Pharmaceutical Sciences Department of Pharmaceutical Sciences Title Associate Professor External Link To the head of this page.▲ Degree 【 display / non-display 】 To the head of this page.▲ Degree 【 display / non-display 】 医学博士 ( 2002.03   大阪大学 ) 薬学修士 ( 1998.03   富山医科薬科大学 ) 薬学学士 ( 1996.03   富山医科薬科大学 ) To the head of this page.▲ Research Areas 【 display / non-display 】 To the head of this page.▲ Research Areas 【 display / non-display 】 Life Science / Clinical pharmacy To the head of this page.▲ From School 【 display / non-display 】 To the head of this page.▲ From School 【 display / non-display 】 Toyama Medical and Pharmaceutical University   Faculty of Pharmaceutical Science   Graduated 1992.04 - 1996.03   More details Country:Japan To the head of this page.▲ Studying abroad experiences 【 display / non-display 】 To the head of this page.▲ Studying abroad experiences 【 display / non-display 】 2005.04 - 2008.11   University of Washington   Senior Fellow 2003.11 - 2005.03   University of Washington   To the head of this page.▲ Employment Record in Research 【 display / non-display 】 To the head of this page.▲ Employment Record in Research 【 display / non-display 】 Josai University   Faculty of Pharmaceutical Sciences   Department of Pharmaceutical Sciences   Associate Professor 2018.04 To the head of this page.▲ External Career 【 display / non-display 】 To the head of this page.▲ External Career 【 display / non-display 】 Osaka Ohtani University   Assistant Professor 2014.04 - 2018.03   More details Country:Japan Osaka Ohtani University 2012.10 - 2013.12   More details Country:Japan ワシントン大学   医学部   研究員 2005.04 - 2008.11   More details Country:United States ワシントン大学   医学部   日本学術振興会特別研究員 2003.11 - 2005.03   More details Country:United States Osaka University   Special researcher of the Japan Society for the Promotion of Science 2002.04 - 2003.10   More details Country:Japan display all >> To the head of this page.▲ Professional Memberships 【 display / non-display 】 To the head of this page.▲ Professional Memberships 【 display / non-display 】 日本リンパ学会 2018.10 コントロールリリース学会 (Controlled Release Society) 2016.04 遺伝子・デリバリー研究会 2016.04 日本薬学会 2014.04 日本DDS学会 2014.04 display all >> To the head of this page.▲   Research Career 【 display / non-display 】 To the head of this page.▲ Research Career 【 display / non-display 】 再発性悪性リンパ腫の完全根治を目指したリンパ移行性腫瘍標的型核酸製剤の創製 Grant-in-Aid for Scientific Research   Project Year: 2021.04  -    核酸医薬品へのパラダイムシフトを加速する経口核酸送達システムの開発研究 Grant-in-Aid for Scientific Research   Project Year: 2018.04  -    三次元腸管粘膜再構築モデルの作製と核酸製剤を用いた基礎的評価 Grant-in-Aid for Scientific Research   Project Year: 2014.04  -    画期的な新規核酸医薬の分子技術の創出 JST Basic Research Programs (Core Research for Evolutional Science and Technology :CREST)   Project Year: 2012.10  -  2018.03  肝臓に対する新規DDSを活用した経口遺伝子治療法の開発 Health and Labour Sciences Research Grants   Project Year: 2011.04  -  2012.03  display all >> To the head of this page.▲ Papers 【 display / non-display 】 To the head of this page.▲ Papers 【 display / non-display 】 Caco-2 Cell Sheet Partially Laminated with HT29-MTX Cells as a Novel In Vitro Model of Gut Epithelium Drug Permeability Invited Reviewed International journal Yi Cheng, Chie Watanabe, Yusuke Ando, Satoshi Kitaoka, Yuya Egawa, Tomoya Takashima, Akihiro Matsumoto, Masahiro Murakami Pharmaceutics   15 ( 9 )   2338   2023.09  More details Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   DOI: 10.3390/pharmaceutics15092338 Regulation of B-lineage cells by caspase 6. Reviewed International journal C. Watanabe, G.L. Shu, N.V. Giltay, E. A. Clark Immunology and Cell Biology   1 - 11   2018.06  More details Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley   The caspase (Casp) family of proteases regulate both lymphocyte apoptosis and activation. Here, we show that Casp6 regulates early B-cell development. One-week-old Casp6 knockout (Casp6 KO) mice have significantly more splenic B-cell subsets than wild-type (WT) mice. Adult Casp6 KO mice have normal levels of total splenic B cells but have increased numbers of B1a B cells and CD43+ "transitional" or splenic red pulp (RP) B cells. These results suggested that Casp6 may function to control B-cell numbers under nonhomeostatic conditions and during B-cell development. Consistent with this model, reconstitution of B cells was dysregulated in Casp6 KO mice after sublethal irradiation. Furthermore, bone marrow pro-B, pre-B and immature B-cell numbers were significantly higher in 1-week-old Casp6 KO mice than in 1-week-old WT mice. Casp6 KO pro-B cells proliferated more in response to IL-7 than WT pro-B cells, suggesting that Casp6 regulates early B-cell responses to IL-7. Indeed, adult and aged Casp6 KO mice had elevated numbers of IL-7αR+ Sca1+ precursors of common lymphoid progenitors, suggesting Casp6 may help regulate progenitors of B cells and early B-lineage cells. Casp6 regulates B-cell programs both during early development and after antigen stimulation in the periphery. DOI: 10.1111/imcb.12172 PubMed Other Link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/imcb.12172 Janus microspheres for enhanced enteral drug delivery: Preparation and orientated attachment to a Caco-2 monolayer. Reviewed International journal Akihiro Matsumoto, Chie Watanabe, Masahiro Murakami Drug Discoveries & Therapeutics   13 ( 6 )   343 - 353   2019.12  More details Authorship:Second author   Language:English   Publishing type:Research paper (scientific journal)   Publisher: International Advancement Center for Medicine & Health Research Co., Ltd.   Conventional oral preparations generally release incorporated drugs omnidirectionally, including into the lumen, leading to a low bioavailability of drugs that are unstable in the gastrointestinal tract. Here, we designed Janus microspheres for efficient mucosal drug delivery as single-sided-release microspheres with the oriented attachment to mucus and evaluated their attachment to and orientation on a Caco-2 (human Caucasian colon adenocarcinoma cell line) monolayer. The microspheres comprised a mucus-oriented hemisphere of an ammonioalkyl methacrylate copolymer and a protective hemisphere of a hard fat. Fluorescein isothiocyanate-dextran with an average molecular weight of 3,000-5,000 Da (FD4) was used as a model hydrophilic drug. A water-in-oil emulsion-type solvent evaporation method was employed for fabrication of the Janus microspheres. The yield of Janus microspheres was found to be dependent on the polymer-to-hard fat ratio, with a maximum yield of over 90% being obtained at a ratio of 1:2, whereas lower and higher ratios resulted in monolithic or star-shaped microspheres. FD4 was specifically localized in the polymeric hemisphere. A cell culture study revealed that the Janus microspheres attached to a Caco-2 monolayer via their polymeric hemispheres with the hard fat hemisphere providing a protective sealing. This may lead to the development of an effective enteral drug delivery system for biomedicines, such as polypeptides and nucleic acids. DOI: 10.5582/ddt.2019.01090 PubMed Other Link: https://www.jstage.jst.go.jp/article/ddt/13/6/13_2019.01090/_article Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route. Reviewed International journal M.Murakami, K.Nishina, C.Watanabe, K.Yoshida-Tanaka, W.Piao, H.Kuwahara, Y.Horikiri, K.Miyata, N.Nishiyama, K.Kataoka, M.Yoshida, H.Mizusawa, T.Yokota Scientific Reports   5   17035 - 17047   2015  More details Authorship:Second author   Language:English   Publishing type:Research paper (scientific journal)   核酸医薬開発において、世界で初めて、局所注射や静脈注射以外の方法による全身性標的型デリバリーを、ビタミンE修飾型siRNAを用いた経腸経リンパデリバリーシステムの開発により成功し、実証した。 Caspase-6 regulates B cell activation and differentiation into plasma cells. Reviewed International journal C. Watanabe, G. L. Shu, T. Zheng, R. A. Flavell, E. A. Clark Journal of Immunology   181 ( 10 )   8810 - 8819   2008  More details Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   display all >> To the head of this page.▲ Books and Other Publications 【 display / non-display 】 To the head of this page.▲ Books and Other Publications 【 display / non-display 】 DDS先端技術の製剤への応用開発 村上正裕、渡辺知恵( Role: Joint author ,  トコフェロール修飾による直腸からの肝標的デリバリー技術) (株)技術情報協会  2017.08   More details Language:English   Book type:Scholarly book 接着分子ハンドブック (担当項目:CD40L) 渡辺知恵, 菊谷仁( Role: Contributor ,  CD40L) 秀潤社  2000   More details Responsible for pages:CD40L   Language:Japanese   Book type:General book, introductory book for general audience 接着分子ハンドブック (担当項目:CD40) 渡辺知恵, 菊谷仁( Role: Contributor ,  CD40) 秀潤社  2000   More details Responsible for pages:CD40   Language:Japanese   Book type:Scholarly book To the head of this page.▲ Misc 【 display / non-display 】 To the head of this page.▲ Misc 【 display / non-display 】 経口核酸医薬開発へのアプローチ Invited 村上正裕、渡辺知恵 36 ( 14 )   85(1429) - 91(1435)   2021.12  More details Authorship:Last author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Can colorectal delivery technology provide a platform for enteral oligonucleotide-based therapeutics? Reviewed International journal M.Murakami, C.Watanabe Drug Discoveries & Therapeutics   10 ( 5 )   273 - 275   2016.11  More details Authorship:Second author   Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   核酸医薬に基づく治療法の経口剤開発における経腸デリバリーの利点について論じた。 The mechanisms of immune regulation by semaphorins. Invited 渡辺知恵 細胞工学   21 ( 11 )   1298 - 1303   2002  More details Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Enhanced immune responses in transgenic mice over-expressing truncated and soluble forms of the lymphocyte semaphorin CD100/Sema4D International journal C. Watanabe, A. Kumanogoh, W. Shi, X. Wang, T. Yasui, M. Ikawa, M. Okabe, K. Yoshida and H. Kikutani Leucocyte Typing VII   132 - 133   2002  More details Authorship:Lead author   Language:English   Publishing type:Article, review, commentary, editorial, etc. (international conference proceedings)   Publisher:Oxford University Press Inc.   Costimulatory signals of CD100 by turning off negative signaling of CD72. Invited C. Watanabe and A. Kumanogoh 臨床免疫   36 ( 3 )   359 - 365   2001  More details Authorship:Lead author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   display all >> To the head of this page.▲ Presentations 【 display / non-display 】 To the head of this page.▲ Presentations 【 display / non-display 】 Systemic liver-targeting delivery of a novel DNA/RNA heteroduplex oligonucleotide via an enteral route Invited International conference Chie Watanabe, Masahiro Murakami 3rd edition of Global Conference on Pharmaceutics and Drug delivery systems  Magnus Group Conference  More details Event date: 2019.06 Language:English   Presentation type:Oral presentation (invited, special)   Venue:Paris, France   Since the advent of antisense technology, oligonucleotide drugs have attracted a greater deal of attention as next-generation therapeutics, which can be selectively delivered to their target tissue to obtain effective gene silencing. The production of conventional pharmaceutical preparations considering factors such as the oral and rectal dosage form is an essential step in the development of a wide range of oligonucleotide drugs. However, oligonucleotides are macromolecules that are easily disintegrated by nucleases and as such, are generally poorly absorbed by the intestine. We have recently developed a hepatocyte-specific delivery technique for oligonucleotides via an enteral route. The chemical conjugation of siRNA with alpha-tocopherol utilized chylomicrons, which acted as a specific in vivo carrier to the liver and were formulated as lipid nanoparticles using unsaturated fatty acid as an absorption enhancer. The method demonstrated effective silencing of the targeted mRNA (ApoB) expression in mice in a postprandial state (Murakami, et al, Sci. Rep. 2015). In this talk, we will provide an overview of the concept of our enteral delivery technique and discuss our recent results on the development of a DNA/RNA heteroduplex oligonucleotide (HDO) which was newly prepared as a more specific and potent oligonucleotide drug (Nishina K., et al. Nat. Commun., 2015). We used a tight junction (TJ) modulator as a para-cellular specific permeation enhancer (Takahashi A, et al., Biomaterials, 2012) and demonstrated that the HDO conjugate with alpha-tocopherol specifically delivered to the liver following rectal administration of the enema in mice and suppressed ApoB gene expression, consequently achieved the reduction of plasma triglyceride and cholesterol levels in the model mice with hypercholesterolemia. These findings suggest that our enteral delivery technique via the lymphatic route should be useful for developing a non-invasive conventional preparation for oligonucleotide therapeutics. Applicability of this technology to the other organ-specific oligonucleotide delivery systems using conjugates with different targeting molecules or ligands remains to be investigated. Rectal delivery of a novel DNA/RNA heteroduplex antisense oligonucleotide for ApoB improves hypercholesterolemia in a mouse model International conference C.Watanabe, Y. Cheng, A. Watari, M. Kondoh, K Yagi, S. Obika, K. Yoshida-Tanaka, K. Yoshioka, T. Yokota, M. Murakami 14th US-Japan DDS symposium   More details Event date: 2017.12 Language:English   Presentation type:Oral presentation (general)   Venue:Lahanina, HI, USA   Liver-specific delivery of a novel DNA/RNA heteroduplex oligonucleotide via enteral routes produced by the combination of alpha-tocopherol conjugation and permeation enhancers. International conference C. Watanabe, Y.Cheng, A. Watari, M.Kondoh, K. Yagi, Y. Matsumoto, K. Toh, K. Miyata, K. Kataoka, S. Obika, K.Yoshida-Tanaka, K. Nishina. T. Yokota, M. Murakami Controlled Release Society   More details Event date: 2016.07 Language:English   Presentation type:Oral presentation (general)   Venue:Seattle, Washington, USA   新規ヘテロ核酸を各種タイトジャンクション修飾剤を吸収促進剤として用いてマウス腸管内に投薬した所、経腸デリバリーに成功したことを報告した。 Combination of Vitamin-E conjugation with lipid nanoparticle formulation as a novel enteral delivery technology for a systemic liver targeting of therapeutic oligonucleotides Invited International conference C. Watanabe, K. Nishina, T. Yokota, M. Murakami BIT’s 14th annual congress of international drug discovery science and technology-2016   More details Event date: 2016.06 Language:English   Presentation type:Oral presentation (invited, special)   Venue:韓国   油脂・ポリマー異方性粒子の形態と薬物分布に関する検討 松本昭博、村尾聡、渡辺知恵、村上正裕 日本薬学会第137年会   More details Event date: 2017.03 Language:Japanese   Presentation type:Poster presentation   Venue:仙台、日本   To the head of this page.▲ Scientific Research Funds Acquisition Results 【 display / non-display 】 To the head of this page.▲ Scientific Research Funds Acquisition Results 【 display / non-display 】 再発性悪性リンパ腫の完全根治を目指したリンパ移行性腫瘍標的型核酸製剤の創製 Grant number:21K07224  2021.04 - 2023.03 日本学術振興会  科学研究費補助金  2021年度 基盤研究(C)   More details Authorship:Principal investigator  変形性膝関節症における再生医療適応の判定基準および治療アルゴリズムの確立 Grant number:22K12893  2022.04 - 2025.03 日本学術振興会  科学研究費補助金  2022年度 基盤研究(C) 松田芳和、安藤祐介   More details Authorship:Coinvestigator(s)  多孔性ヤヌス微粒子による経口核酸デリバリーの最適化と吸収過程の局所モデル化の試み Grant number:22K12828  2022.04 - 2025.03 日本学術振興会  科学研究費補助金  2022年度 基盤研究(C) 松本明博、村上正裕   More details Authorship:Coinvestigator(s)  To the head of this page.▲   Social Activities 【 display / non-display 】 To the head of this page.▲ Social Activities 【 display / non-display 】 できる薬剤師のための病態学シリーズ Role(s): Lecturer 特定非営利活動法人 医療教育研究所  2020.01  More details Type:Internet 夢ナビ Role(s): Lecturer 株式会社 フロムページ  夢ナビライブ  2020.09  More details Audience: High school students Type:Science festival 全国の高校生を対象とし、多数の大学と講師陣が模擬授業を行い、学生の進路決定に役立てるイベントにおいて、薬学とは、「病態学」から「薬剤学」まで、薬の役割、薬学の役割を模擬授業の中で説明し、2日にわたりZOOMによる直接の質疑応答を行った。 To the head of this page.▲   Copyright © Josai University, All Rights Reserved.

1XBET – オンラインスポーツベッティング - ブックメーカー ... オンラインカジノ バカラのやり方・遊び方ガイド【おすすめ ... インターカジノ出金できない valorantガーディアン
Copyright ©バカラツリー The Paper All rights reserved.